Cargando…

Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors

The development of new antidiabetes agents is necessary to obtain optimal glycemic control and overcome its complications. Different quinazolin-4(3H)-one bearing phenoxy-acetamide derivatives (7a–r) were designed and synthesized to develop α-glucosidase inhibitors. All the synthesized derivatives we...

Descripción completa

Detalles Bibliográficos
Autores principales: Moheb, Mahshid, Iraji, Aida, Dastyafteh, Navid, Khalili Ghomi, Minoo, Noori, Milad, Mojtabavi, Somayeh, Faramarzi, Mohammad Ali, Rasekh, Fatemeh, Larijani, Bagher, Zomorodian, Kamiar, Sadat-Ebrahimi, Seyed Esmaeil, Mahdavi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667588/
https://www.ncbi.nlm.nih.gov/pubmed/36380337
http://dx.doi.org/10.1186/s13065-022-00885-z
Descripción
Sumario:The development of new antidiabetes agents is necessary to obtain optimal glycemic control and overcome its complications. Different quinazolin-4(3H)-one bearing phenoxy-acetamide derivatives (7a–r) were designed and synthesized to develop α-glucosidase inhibitors. All the synthesized derivatives were evaluated against α-glucosidase in vitro and among them, compound 7b showed the highest α-glucosidase inhibition with an IC(50) of 14.4 µM, which was ∼53 times stronger than that of acarbose. The inhibition kinetic studies showed that the inhibitory mechanism of compound 7b was a competitive type towards α-glucosidase. Also, molecular docking studies analyzed the interaction between the most potent derivative and α-glucosidase. Current findings indicate the new potential of quinazolin-4(3H)-ones that could be used for the development of novel agents against diabetes mellitus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-022-00885-z.